Med (New York, N.Y.) · 2026
Efficacy of immunotherapy rechallenge in locoregionally advanced nasopharyngeal carcinoma after progression: A real-world analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Jia-Rui, Li Yu-Xin, Liu Bao-Cong, Zhang Qi-Tong, Chen Jie, Cheng Hui, Xiao Yu-Xi, Tse Chun-Fung, Li Yi-Fu, Wu Lin-Fang, Guo Hong-Bo, Liang Yu-Jing, Sun Xue-Song, Li Xiao-Yun, Chen Qiu-Yan, Tang Lin-Quan, Mai Hai-Qiang, Liu Li-Ting
Аннотация
BACKGROUND: Recent clinical trials have suggested that incorporating immunotherapy into the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC) may improve survival outcomes. However, for patients who experience disease progression despite immunotherapy, the clinical value of immunotherapy rechallenge as a first-line treatment for recurrent or metastatic disease remains unclear.
METHODS: In this real-world study, patients with LA-NPC who received immunotherapy during the initial treatment and subsequently experienced disease progression were retrospectively analyzed. All patients received first-line treatment with or without immunotherapy rechallenge after progression. The primary endpoint was progression-free survival after the first relapse (PFS-r).
FINDINGS: From a total of 24,183 consecutive patients screened between 2018 and 2023, 160 met the eligibility criteria and were included, with 117 receiving immunotherapy rechallenge and 43 receiving non-immunotherapy treatment after progression. The median follow-up time was 39.3 months (interquartile range, 26.0-48.4). After inverse probability of treatment weighting adjustment, immunotherapy rechallenge did not confer a significant survival advantage in the overall cohort (2-year PFS-r, 40.8% vs. 26.2%; hazard ratio [HR] = 0.677, 95% confidence interval [CI] 0.419-1.094, p = 0.111). Subgroup analyses showed that, in patients with an immunotherapy-free interval >1 year, immunotherapy rechallenge was associated with a significantly improved prognosis (2-year PFS-r, 65.4% vs. 15.5%; HR = 0.210, 95% CI 0.093-0.474, p < 0.001).
CONCLUSIONS: Immunotherapy rechallenge may not provide a significant survival benefit following initial immunotherapy failure in LA-NPC, except in patients with an immunotherapy-free interval exceeding 1 year.
FUNDING: National Natural Science Foundation of China and Science and Technology Program of Guangzhou.
METHODS: In this real-world study, patients with LA-NPC who received immunotherapy during the initial treatment and subsequently experienced disease progression were retrospectively analyzed. All patients received first-line treatment with or without immunotherapy rechallenge after progression. The primary endpoint was progression-free survival after the first relapse (PFS-r).
FINDINGS: From a total of 24,183 consecutive patients screened between 2018 and 2023, 160 met the eligibility criteria and were included, with 117 receiving immunotherapy rechallenge and 43 receiving non-immunotherapy treatment after progression. The median follow-up time was 39.3 months (interquartile range, 26.0-48.4). After inverse probability of treatment weighting adjustment, immunotherapy rechallenge did not confer a significant survival advantage in the overall cohort (2-year PFS-r, 40.8% vs. 26.2%; hazard ratio [HR] = 0.677, 95% confidence interval [CI] 0.419-1.094, p = 0.111). Subgroup analyses showed that, in patients with an immunotherapy-free interval >1 year, immunotherapy rechallenge was associated with a significantly improved prognosis (2-year PFS-r, 65.4% vs. 15.5%; HR = 0.210, 95% CI 0.093-0.474, p < 0.001).
CONCLUSIONS: Immunotherapy rechallenge may not provide a significant survival benefit following initial immunotherapy failure in LA-NPC, except in patients with an immunotherapy-free interval exceeding 1 year.
FUNDING: National Natural Science Foundation of China and Science and Technology Program of Guangzhou.